Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Summary

This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786, as compared with placebo, for the treatment of negative symptoms of schizophrenia.

Timeline

Start

2019-02-15

Primary completion

2023-05-23

Completion

2023-05-23

Outcome

Outcome not reported

Stopped: “Based on the Interim Analysis outcome and recommendation by the DMC, Otsuka approved termination of the study based on futility.”

Drugs

Indications